Comparative Pharmacology
Head-to-head clinical analysis: ANKTIVA versus PROLEUKIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANKTIVA versus PROLEUKIN.
ANKTIVA vs PROLEUKIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ANKTIVA is a live attenuated, nonpathogenic recombinant strain of Vibrio cholerae O1 (CVD 103-HgR) that colonizes the intestinal mucosa and elicits protective mucosal and systemic immune responses against V. cholerae, including production of vibriocidal and antitoxin antibodies.
Recombinant interleukin-2 (IL-2) that activates cellular immunity by promoting proliferation and differentiation of T cells, natural killer cells, and lymphokine-activated killer cells; stimulates cytokine release including TNF, IL-1, and IFN-gamma.
Intravesical instillation of 300 mg (25 mL) once weekly for 6 weeks, followed by maintenance therapy of 300 mg once monthly for 6 or 12 months.
600,000 IU/kg (0.037 mg/kg) intravenously every 8 hours for 14 doses, repeated after 9 days for a maximum of 28 doses per course.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours; clinically, steady-state reached after 2-3 days
Terminal elimination half-life is approximately 85 minutes (range 25-195 minutes) after intravenous infusion; clinical context: short half-life necessitates continuous infusion for sustained immunomodulatory effect.
Renal: ~70% unchanged; fecal: ~30% as metabolites
Renal (primarily via glomerular filtration and tubular reabsorption with subsequent metabolism; <1% excreted unchanged in urine); fecal/biliary elimination is negligible.
Category C
Category C
Immunomodulator
Immunomodulator